Abstract:Recent and advanced methodologies have enhanced the understanding of the immune system features in multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, facilitating the development of personalised therapies. The current collection of articles offers new insights into MS pathology and immunology, identifying therapeutic targets and biomarkers. The articles explore various topics, including immunological biomarkers for predicting treatment success, risks of developing secondary autoimmune conditions, PML, and resistance to disease-modifying therapies. The studies also contribute to elucidating some of the pathological roles of cytotoxic B and T cells, dysfunctional humoral regulatory immunity, and inflammatory cascades triggered by EBV reactivation in the CNS. Additionally, the collection highlights emerging biomarkers of disease activity, offering a comprehensive view of the latest advancements in MS research. Out of the submitted works, nineteen articles were accepted and included in this special issue. Below, we outline the key findings from each study. Several studies have used experimental autoimmune encephalomyelitis (EAE) animal models to explore potential MS treatments. Tang et al. found that T-cell immunoglobulin mucin domain 3 (Tim-3), expressed on immune cells like T cells and macrophages, may inhibit MHC-II-mediated autoantigen presentation and CD4+ T cell activation, influencing EAE outcomes. Targeting the Tim-3/MHC-II signalling pathway could offer new therapeutic options for MS. Hou and Yuki characterised two CCR6+CD4 T cell subsets, showing that one has cytotoxic markers and Th17-related molecules, while another expresses IFNγ and GM-CSF, both contributing to CNS inflammation. These cells could be key targets for future MS therapies.Hu Lu, Peng-Fei and colleagues indicated that lower levels of fibroblast growth factor (FGF) 23 in the blood are associated with an increased risk of MS, although further investigation is needed to confirm FGF23 as a potential target for treating MS and to understand the mechanism by which FGF23 contributes to the risk of MS.The overview by Meier et al. suggests a central role for Epstein-Barr virus (EBV) in the dysregulation of immune responses and neuronal damage seen in multiple sclerosis (MS). After EBV reactivation in latent B-cells, it could trigger immune complexes and anti-EBNA1-IgG production, leading to a cascade of immune responses involving T, B, NK cells, and cytokines (Type-I IFN, TNF-α, IL-6, -10, -17A). This causes localised inflammation, which, combined with a compromised blood-brain barrier, leads to CNS glia activation and inflammatory lesions. Additionally, this process may activate endogenous viral sequences (MSRV, HERV-K/-W, HHV6A), further intensifying CNS inflammation.Several studies have highlighted the role of long non-coding RNAs (lncRNAs) in neurodegenerative diseases. Tamizkar et al. found that the differential expression of five specific lncRNAs in the blood can distinguish Parkinson's disease (PD) patients from healthy donors. In multiple sclerosis (MS), Jalalei et al. identified 52 upregulated, 37 downregulated, and 11 stable lncRNAs in MS patients, suggesting that lncRNA dysregulation may contribute to neuronal death through unknown RNA-based mechanisms. Additionally, bioinformatic analysis by Sabaie et al. revealed that lncRNA SNHG1 might regulate protein processing in T-cell signaling in relapsing-remitting MS (RRMS) patients, although further research is needed to understand the molecular mechanisms underlying neurodegeneration.Yalachkov et al. highlight the importance of examining peripheral and central inflammation markers at MS diagnosis to understand their connection to depressive symptoms Additionally, investigation from Meng Li et al. suggests that IL-17A, Del-1, and Resolvin D1 may co-regulate MS progression, providing insights into therapeutic targets and patient prognosis. Furthermore, a prognostic model using microarray gene expression data shows promise for effectively classifying MS patients and could serve as a valuable diagnostic tool (Haoran Li et al.).

The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis

Myeloid-derived Suppressor Cells and Multiple Sclerosis

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy

T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis

CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade

Editorial: Community series in reassessing the immune system contribution in multiple sclerosis: therapeutic target, biomarkers of disease and immune pathogenesis, volume II

Altered Ligand-Interaction Contributes to Functional Insufficiency Due to CTLA-4 Gene Mutation

The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis

Current understanding of CTLA-4: from mechanism to autoimmune diseases

Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis

Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

T cells in the pathogenesis of multiple sclerosis and related therapy

Therapeutic options for CTLA-4 insufficiency

Elucidating CTLA-4's role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments

Roles of miRNA, lcnRNA, and circRNA and Their Implications in Cellular Pathways

Anti-MS4a4B Treatment Abrogates MS4a4B-mediated Protection in T Cells and Ameliorates Experimental Autoimmune Encephalomyelitis.

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis.

Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice